Journal of Infectious Diseases and Treatment
ISSN: 2472-1093

Open access Commentary

COVID-19 and the Effects on Alzheimer Pathology

Oscar Artega*

Department of Pathology, University of California, USA

DESCRIPTION

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has brought about a global health crisis with far-reaching consequences. Beyond its immediate respiratory effects, emerging research suggests that COVID-19 may have implications for neurodegenerative diseases, including Alzheimer's disease (AD). This intersection of infectious disease and neurology presents a complex area of study, raising questions about the potential impact of COVID-19 on Alzheimer's disease pathology. One avenue of concern lies in the virus's potential to directly affect the central nervous system (CNS). SARS-CoV-2 has been detected in the brain tissue of infected individuals, indicating its capacity to breach the blood-brain barrier. This raises the possibility of direct neuronal infection and neuroinflammatory responses. In AD, neuroinflammation is a hallmark feature, characterized by the activation of microglial cells and release of pro-inflammatory cytokines. The presence of a viral infection in the CNS could potentially exacerbate this inflammatory response, further accelerating the neurodegenerative process. Additionally, COVID-19 has been associated with a range of neurological symptoms, often referred to as "COVID-19-associated neurological complications" (CANCs). These include encephalopathy, anosmia, and cerebrovascular events. The occurrence of these neurological manifestations raises questions about the potential long-term consequences, particularly in individuals with pre-existing neurodegenerative conditions like Alzheimer's disease. It is plausible that the presence of COVID-19 could exacerbate cognitive decline and worsen the clinical trajectory of AD patients. Moreover, the systemic effects of COVID-19, including inflammation, hypoxia, and coagulopathy, may indirectly influence AD pathology. Chronic inflammation, as observed in severe COVID-19 cases, can contribute to neuro degeneration and the accumulation of pathological proteins, such as beta-amyloid plaques in AD. Hypoxia, or reduced oxygen supply, is a common complication in severe COVID-19 cases and has been linked to cognitive impairment and neuronal damage. Coagulopathy, characterized by abnormal blood clotting, may lead to microvascular changes that impact cerebral blood flow, potentially exacerbating neurodegenerative processes. The impact of COVID-19 on the immune system also merits consideration in the context of Alzheimer's disease. Dysregulated immune responses, as seen in severe cases of COVID-19, can have implications for neuroinflammation and the clearance of pathological proteins. The immune system's ability to effectively clear beta-amyloid plaques, a characteristic feature of AD, may be compromised in individuals recovering from severe COVID-19. This could potentially lead to accelerated accumulation of amyloid deposits and hastened cognitive decline. Furthermore, the social and psychological ramifications of the pandemic may indirectly affect Alzheimer's disease pathology. Isolation, stress, and disruptions in routine can contribute to worsened cognitive function and behavioral symptoms in individuals with AD. The challenges posed by the pandemic, including restrictions on social interactions and changes in caregiving routines, may exacerbate these issues. The interplay between COVID-19 and Alzheimer's disease pathology is a multifaceted area of research with important implications for clinical practice. While direct viral effects on the CNS and the presence of COVID-19-associated neurological complications raise concerns, it is equally crucial to consider the indirect systemic effects and the potential long-term consequences of the pandemic on AD patients. Continued research in this area is essential for a comprehensive understanding of the complex relationship between infectious diseases and neurodegenerative conditions.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The author declares there is no conflict of interest in publishing this article.

Received:	30-August-2023	**Manuscript No:**	IPJIDT-23-18075
Editor assigned:	01-September-2023	**PreQC No:**	IPJIDT-23-18075 (PQ)
Reviewed:	15-September-2023	**QC No:**	IPJIDT-23-18075
Revised:	20-September-2023	**Manuscript No:**	IPJIDT-23-18075 (R)
Published:	27-September-2023	**DOI:**	10.36648/2472-1093-9.9.84

Corresponding author Oscar Artega, Department of Pathology, University of California, USA, E-mail: OscarArtega4254@yahoo.com

Citation Artega O (2023) COVID-19 and the Effects on Alzheimer Pathology. J Infect Dis Treat. 9:84.